share_log

Maccura BiotechnologyLtd's (SZSE:300463) Soft Earnings Are Actually Better Than They Appear

Maccura BiotechnologyLtd's (SZSE:300463) Soft Earnings Are Actually Better Than They Appear

Maccura BioTechnologyLtd(深圳證券交易所代碼:300463)的軟收益實際上比看起來要好
Simply Wall St ·  05/01 19:13

Maccura Biotechnology Co.Ltd's (SZSE:300463) recent soft profit numbers didn't appear to worry shareholders, as the stock price showed strength. We think that investors might be looking at some positive factors beyond the earnings numbers.

由於股價表現強勁,Maccura Biotechnology Co.td(深圳證券交易所股票代碼:300463)最近的疲軟利潤數字似乎並沒有讓股東感到擔憂。我們認爲,除了收益數字外,投資者可能會考慮一些積極因素。

earnings-and-revenue-history
SZSE:300463 Earnings and Revenue History May 1st 2024
SZSE: 300463 收益和收入歷史記錄 2024 年 5 月 1 日

The Impact Of Unusual Items On Profit

不尋常物品對利潤的影響

To properly understand Maccura BiotechnologyLtd's profit results, we need to consider the CN¥60m expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. If Maccura BiotechnologyLtd doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

爲了正確了解Maccura BioTechnologyLtd的利潤業績,我們需要考慮歸因於不尋常項目的6000萬元支出。儘管由於不尋常項目而產生的扣除首先令人失望,但有一線希望。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。鑑於這些單列項目被認爲不尋常,這並不奇怪。如果Maccura BioTechnologyLtd不認爲這些不尋常的支出重演,那麼在其他條件相同的情況下,我們預計其利潤將在來年增加。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On Maccura BiotechnologyLtd's Profit Performance

我們對馬庫拉生物技術有限公司盈利表現的看法

Unusual items (expenses) detracted from Maccura BiotechnologyLtd's earnings over the last year, but we might see an improvement next year. Because of this, we think Maccura BiotechnologyLtd's earnings potential is at least as good as it seems, and maybe even better! On the other hand, its EPS actually shrunk in the last twelve months. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. So while earnings quality is important, it's equally important to consider the risks facing Maccura BiotechnologyLtd at this point in time. For example - Maccura BiotechnologyLtd has 2 warning signs we think you should be aware of.

不尋常的項目(支出)減少了Maccura BioTechnologyLtd去年的收益,但明年我們可能會看到改善。因此,我們認爲Maccura BioTechnologyLtd的盈利潛力至少和看起來一樣好,甚至可能更好!另一方面,其每股收益實際上在過去十二個月中萎縮了。歸根結底,如果你想正確地了解公司,必須考慮的不僅僅是上述因素。因此,儘管收益質量很重要,但考慮Maccura BioTechnologyLtd目前面臨的風險同樣重要。例如,Maccura BioTechnologyLtd 有兩個警告信號,我們認爲你應該注意。

This note has only looked at a single factor that sheds light on the nature of Maccura BiotechnologyLtd's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

這份報告只研究了揭示Maccura BioTechnologyLtd利潤性質的單一因素。但是,還有很多其他方法可以讓你對公司的看法。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論